-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data ---- Aligned with U.S. Food and Drug Administration on Registrational Path for Luvesilocin in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 --  MORRISTOWN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychede ...

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.Leerink Partners 2026 Global Healthcare Conference, firesid ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics E ...

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences: TD Cowen 46th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm ESTLeerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat on Tuesday, ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. “We are delighted to wel ...

Core Viewpoint - PCI Biotech Holding ASA is proposing to dissolve the company and delist its shares from Euronext Oslo Børs due to the absence of operational activity and the expectation that such activity will not resume [2][3]. Group 1: Company Dissolution - The Board of Directors has proposed the resolution to dissolve PCI Biotech as there is no longer any operational activity within the company [2]. - The wholly owned subsidiary, PCI Biotech AS, has also resolved to initiate a parallel dissolution process [2]. Group 2: Delisting from Euronext Oslo Børs - The proposed resolution to delist the shares is based on the lack of operational activity and a limited asset base, leading the Board to conclude that the company is no longer suitable for public trading [3]. - The Board recommends that the delisting should occur as soon as possible [3].

Core Viewpoint - Rail Vision Ltd. has regained compliance with Nasdaq's minimum bid price requirement after its stock price was above $1.00 for 10 consecutive business days, resolving a previous non-compliance issue [1][2][3]. Company Overview - Rail Vision is an early commercialization stage technology company focused on enhancing railway safety and the rail data market through advanced artificial intelligence technology [4]. - The company's technology aims to save lives, increase efficiency, and significantly reduce costs for railway operators, while also contributing to the potential realization of autonomous trains [4].

Core Insights - North Media announced preliminary, unaudited financial results for 2025 and provided financial guidance for 2026 [1] Financial Performance for 2025 - Revenue for 2025 was DKK 1,296 million, aligning with the latest guidance of DKK 1,270 – 1,305 million [2] - EBITDA for 2025 was DKK 125 million, down 19% from the previous year, primarily due to integration costs of SDR and lower revenue in FK Distribution [2] - EBIT for 2025 was DKK 66 million, an improvement from DKK -75 million in 2024, with an EBIT margin of 5.2% [2] Segment Performance - In the Last Mile segment, revenue decreased by 1% to DKK 1,132 million, attributed to a decline in FK Distribution's volume, while SDR's revenue increased by 2% [2] - In the Digital Services segment, revenue grew by 1% to DKK 164 million, driven by a 4% increase in BoligPortal, despite a 13% decline in Dayli [3] - EBITDA in Digital Services improved to DKK 9 million from DKK -11 million in 2024, with EBIT rising to DKK 4 million from DKK -17 million in 2024 [3] Cost and Dividend Proposal - Unallocated costs for the Group were DKK 23 million, consistent with 2024 [4] - The Board proposed a dividend of DKK 1.25 per share, reflecting earnings from ordinary operations [4] Financial Guidance for 2026 - Revenue for 2026 is expected to be in line with 2025, with flat development in Last Mile and growth anticipated in Digital Services [5] - An increase in EBITDA and EBIT is expected across all companies, driven by strategic initiatives implemented in 2025 [5] - The annual report for 2025 is scheduled for publication on 25 February 2026 [5] Company Overview - North Media operates platforms that connect businesses and consumers, focusing on two core business areas: Last Mile and Digital Services [8] - Last Mile includes FK Distribution and SDR, leading distributors of leaflets and local newspapers in Denmark and Sweden [8] - Digital Services encompasses BoligPortal, Dayli, and Bekey, with potential for strong growth and scalability [8]

Company Overview - C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation (TPD) science to create innovative medicines that can transform patients' lives [3] - The company is developing targeted oncology programs through clinical studies and utilizes its TORPEDO platform to design and optimize small-molecule medicines for challenging diseases [3] - C4T's degrader medicines aim to leverage the body's natural protein recycling system to degrade disease-causing proteins, potentially addressing drug resistance and improving patient outcomes [3] Upcoming Events - C4T management will participate in the Barclays 28 Annual Global Healthcare Conference on March 10, 2026, at 8:00 AM ET in Miami, Florida, featuring a fireside chat [2] - The company will also present at the TD Cowen 46 Annual Healthcare Conference on March 3, 2026, at 11:50 AM ET in Boston, Massachusetts, where management will engage in a fireside chat [4]

Core Viewpoint - A class action lawsuit has been filed against NuScale Power Corporation and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Oregon, captioned Truedson v. NuScale Power Corporation, et al., No. 3:26-cv-00328 [3]. - Investors have until April 20, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - NuScale Power Corporation specializes in nuclear technology, particularly the NuScale Power Module (NPM), a small modular nuclear reactor designed for energy generation [4]. - The company had established a partnership with ENTRA1 Energy LLC, which was responsible for constructing power generation facilities using NuScale's NPMs [4]. Group 3: Allegations Against ENTRA1 - NuScale allegedly misrepresented ENTRA1's capabilities, claiming it had extensive experience in developing power plants, while in reality, ENTRA1 had never built or operated any significant projects [5][6]. - ENTRA1 was primarily organized to support the activities of its principal, Wadie Habboush, rather than to undertake substantial projects [6]. Group 4: Stock Price Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses from $17 million in the prior year to $519 million in 3Q 2025, largely due to a $495 million payment to ENTRA1 [7]. - Following the disclosure of ENTRA1's lack of experience in nuclear power projects, NuScale's stock price fell by $4.03 per share, a decline of over 12.4%, from $32.46 on November 6, 2025, to $28.43 on November 10, 2025 [7].